IP Library › Granted Patent US 10,233,428
Granted Patent B2
US 10,233,428 · App. 14/922,935 · Granted Mar 19, 2019

Restrictive inverted terminal repeats for viral vectors

Inventors: Curtis Hewitt (Austin, TX); Richard Jude Samulski (Chapel Hill, NC)
Assignee: The University of North Carolina at Chapel Hill
C12N7/00C07K14/005C12N15/86C12N15/8645C12N2750/14122C12N2750/14143C12N2750/14162C12N2750/14322C12N2750/14352C12N2820/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,233,428
App. No.
14/922,935
Granted
Mar 19, 2019
Kind
B2
Abstract

This invention relates to modified parvovirus inverted terminal repeats (ITRs) that do not functionally interact with wild-type large Rep proteins, synthetic Rep proteins that functionally interact with the modified ITRs, and methods of using the same for delivery of nucleic acids to a cell or a subject. The modifications provide a novel Rep-ITR interaction that limits vector mobilization, increasing the safety of viral vectors.

Claims (15)

1. A synthetic large Rep protein comprising a first portion from a first adeno-associated virus (AAV) and a second portion from a second AAV;

wherein one of the first AAV and the second AAV is AAV5 and the other is an AAV other than AAV5;

wherein the synthetic large Rep protein functionally interacts with a synthetic inverted terminal repeat (ITR) comprising a first structural element from the first AAV and a second structural element from the second AAV; and

wherein the synthetic large Rep protein does not functionally interact with a wild-type ITR from the first AAV or with a wild-type ITR from the second AAV; and

wherein said first and second structural element is a nicking stem, a spacer or an RBE.

2. The protein of claim 1 , wherein said protein comprises a third portion and wherein the synthetic large Rep protein functionally interacts with a synthetic ITR comprising the first structural element, the second structural element, and a third structural element.

3. The protein of claim 1 , wherein said first portion comprises an amino acid sequence from about residue 97 to about residues 146-151 of a wild-type AAV5 Rep sequence.

4. The protein of claim 1 , wherein said second portion comprises an amino acid sequence from about residue 149 to about residue 187 of a wild-type AAV2 Rep sequence.

5. The protein of claim 1 , wherein said first portion comprises an amino acid sequence from about residue 97 to about residues 146-151 of a wild-type AAV5 Rep sequence and said second portion comprises an amino acid sequence from about residue 149 to about residue 187 of a wild-type AAV2 Rep sequence.

6. The protein of claim 1 , wherein said first portion comprises an amino acid sequence from about residue 1 to about residues 146-151 of a wild-type AAV5 Rep sequence and said second portion comprises an amino acid sequence from about residue 149 to about residue 621 of a wild-type AAV2 Rep sequence.

7. The synthetic large Rep protein of claim 1 , wherein the AAV other than AAV5 is selected from the group consisting of AAV1, AAV2, AAV3a, AAV3b, AAV4, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, and AAV13.

8. The synthetic large Rep protein of claim 1 , wherein the first AAV is AAV5.

9. The synthetic large Rep protein of claim 8 , wherein the second AAV is AAV2.

10. The synthetic large Rep protein of claim 1 , wherein the first AAV is AAV2.

11. The synthetic large Rep protein of claim 10 , wherein the second AAV is AAV5.

Continuity (3)
Division 13521448
Provisional Application 61294191 · Jan 12, 2010
Related Publication 20160102297A1 · Apr 14, 2016